deltatrials
Completed PHASE3 INTERVENTIONAL NCT00394121

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Long-term Open-label Safety Study With SkyePharma FlutiForm HFA pMDI (100/10 µg and 250/10 µg) in Adult and Adolescent Patients With Asthma

Sponsor: SkyePharma AG

Conditions Asthma
Updated 10 times since 2017 Last updated: Aug 24, 2010 Started: Mar 31, 2006 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00394121, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by SkyePharma AG, it has been updated 10 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted~Feb 2026 – present · 2 months · monthly snapshotCompleted~Feb 2026 – present · 2 months · monthly snapshotCompleted

Change History

10 versions recorded
  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Feb 2026 — Present [monthly]

    Completed PHASE3

  3. Jan 2026 — Present [monthly]

    Completed PHASE3

  4. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE3

  5. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

Show 5 earlier versions
  1. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  2. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • SkyePharma AG
Data source: SkyePharma AG

For direct contact, visit the study record on ClinicalTrials.gov .